<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485159</url>
  </required_header>
  <id_info>
    <org_study_id>115398</org_study_id>
    <nct_id>NCT01485159</nct_id>
  </id_info>
  <brief_title>Airflow Limitation in Cardiac Diseases in Europe</brief_title>
  <acronym>ALICE</acronym>
  <official_title>Airflow Limitation in Cardiac Diseases in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross-sectional, observational study, investigating the point prevalence of Airflow
      Limitation in current or former smokers with established ischemic heart disease. The study
      will recruit up to 3000 patients from cardiology clinics at hospitals across Europe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Airflow limitation (AL) occurs in a number of respiratory diseases including asthma and COPD;
      in middle-aged and older patients it typically represents Chronic Obstructive Pulmonary
      Disease (COPD), and is associated with a high degree of co-morbidity which includes
      cardiovascular diseases (CVD) and risk factors such as hypertension and diabetes.

      COPD often goes undiagnosed, especially in patients with established coronary disease because
      COPD and cardiovascular diseases share a major etiological factor: smoking.

      This cross-sectional, observational study, investigating the prevalence of AL in current or
      former smokers with established ischemic heart disease, aims increase the knowledge and
      understanding of COPD in this patient population, and to highlight the burden of comorbid
      disease in these patient
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Airflow Limitation</measure>
    <time_frame>1 day</time_frame>
    <description>Prevalence of AL as defined by Forced Expired Volume in 1 second (FEV1)/Forced Volume Capacity (FVC) &lt; 0.70 (post bronchodilator)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of AL</measure>
    <time_frame>1 day</time_frame>
    <description>Severity of AL as determined by predicted FEV1 (post-bronchodilator) - mild: ≥80%, moderate: 50-80%, severe: 30-50%, very severe: &lt;30%, or &lt;50% plus chronic respiratory failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prevalence of restrictive AL</measure>
    <time_frame>1 day</time_frame>
    <description>Prevlence of restrictive AL FEV1/FVC ≥0.70 and a predicted FVC &lt;80% (pre bronchodilator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of AL</measure>
    <time_frame>1 day</time_frame>
    <description>Prevalence of AL as defined by FEV1 below the lower limit of normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of past history of AL/COPD</measure>
    <time_frame>1 day</time_frame>
    <description>prevalence of documented evidence of COPD, chronic bronchitis or emphysema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Assessment test™ (CAT)</measure>
    <time_frame>1 day</time_frame>
    <description>Health status questionnaire on burden of airflow limitation (CAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 12 (SF12)</measure>
    <time_frame>1 day</time_frame>
    <description>General health status questionnaire (SF12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Health Profile (CHP)</measure>
    <time_frame>1 day</time_frame>
    <description>Health status questionnaire on burden of cardiac disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare resource utilisation</measure>
    <time_frame>within previous 12 months</time_frame>
    <description>Number of emergency room visits and hopsital admissions</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3000</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>All</arm_group_label>
    <description>All subjects enrolled in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spirometry</intervention_name>
    <description>assessment of lung function by spirometry</description>
    <arm_group_label>All</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      In patients that specifically consent, blood samples will be taken for future analysis of the
      genetic links between COPD and cardiovascular disease
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients attending outpatient cardiology clinics with a history of Ischemic Heart Disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged ≥40 years;

          -  Current or former smokers with ≥10 pack years;

          -  Subjects attending outpatient cardiac clinic (or equivalent) fulfilling any of the
             following criteria:

               1. Documented history of an Ischemic event,

               2. Current diagnosis of stable IHD (including history of acute Myocardial Infarction
                  (MI) and angina pectoris) as diagnosed in accordance with ESC guidelines

               3. Receiving regular therapy for IHD for &gt;1yr, Subjects meeting these criteria will
                  be eligible for the study, even if they have other cardiac diseases or other
                  co-morbidities;

          -  Subjects willing and able to sign study consent form.

        Exclusion Criteria:

          -  Subjects for whom spirometry is contraindicated;

          -  Subjects with recent surgery or MI (within 1 month); lower respiratory tract infection
             or pneumothorax (within 2 months); or stroke (within 12 months);

          -  Subjects with a pre-existing condition which, in the opinion of the investigator,
             would compromise the safety of the subject in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse cedex 09</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neu-Isenburg</city>
        <state>Hessen</state>
        <zip>63263</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>4</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tradate (VA)</city>
        <state>Lombardia</state>
        <zip>21049</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amersfoort</city>
        <zip>3818 ES</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-222 21</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2011</study_first_posted>
  <last_update_submitted>February 20, 2014</last_update_submitted>
  <last_update_submitted_qc>February 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevalence</keyword>
  <keyword>COPD</keyword>
  <keyword>emphysema</keyword>
  <keyword>co-morbidities</keyword>
  <keyword>ischemic heart disease</keyword>
  <keyword>chronic bronchitis</keyword>
  <keyword>spirometry</keyword>
  <keyword>burden</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

